Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Nautilus Biotechnolgy, Inc.

Nautilus Biotechnolgy, Inc. (NAUT) Stock Overview

Explore Nautilus Biotechnolgy, Inc.’s financial performance, market position, analyst ratings, and future outlook.

NAUT●NASDAQ
HealthcareBiotechnology
$1.66
$0.03(1.78%)
U.S. Market opens in 15h 20m

Nautilus Biotechnolgy, Inc. (NAUT)

Meyka AI Score

Z

Key Financials

Market Cap211M
P/E Ratio-3.67
EPS (TTM)$-0.46
ROE-0.35%
Fundamental Analysis

AI Price Forecasts

1 Month$1.66
3 Months$3.00
1 Year Target$3.29

NAUT Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Nautilus Biotechnolgy, Inc. (NASDAQ: NAUT) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of C+, Nautilus Biotechnolgy, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of NAUT on the NASDAQ shows an RSI of 36.65, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $3.29 for the NASDAQ listing.

Key metrics behind Nautilus Biotechnolgy, Inc.'s NASDAQ-traded stock include a P/E ratio of -3.67 and a market capitalization of 211M. Combined with our AI analysis, these give both institutional and retail investors a clear view of NAUT on the NASDAQ.

Price Performance (NASDAQ: NAUT)

1-Day Change
-1.78%
5-Day Change
-1.19%
1-Month Change
-17.00%
3-Month Change
-35.41%
6-Month Change
-25.56%
Year-to-Date (YTD) Change
-14.87%
1-Year Change
112.17%
3-Year Change
-45.75%
5-Year Change
-79.51%
All-Time (Max) Change
-84.10%

Contact Information

https://www.nautilus.bio
206 333 2001
2701 Eastlake Avenue East, Seattle, WA, 98102

Company Facts

1,270 Employees
IPO DateAug 7, 2020
CountryUS
Actively Trading

Frequently Asked Questions